Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.19), $0.04 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $25.6 million versus the consensus estimate of $30.42 million.

GUIDANCE:

Halozyme Therapeutics sees FY2018 revenue of $150-160 million, versus the consensus of $127.8 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.